I'm amazed to see just how much the AI x Bio trend is accelerating. Models & datasets on Hugging Face are growing fast across DNA/RNA, proteins, small molecules & single-cell. At Converge Bio, we build solutions powered by biological foundation models applied to real R&D.

Instead of looking at the S&P500 go down, you can look at the number of biological models and datasets on Hugging Face go up.

At Converge Bio we are building AI-powered solutions across the entire drug life cycle, from R&D to production, such as binder design, transcript optimization target discovery, and drug MoC with RNA single-cell sequencing

🎙️ Excited to share my recent conversation with Ben from Ben | The SaaS CFO on his podcast! We dive into the future of biotech and our work at Converge Bio . Tune in here: 🍏 Apple Podcasts:podcasts.apple.com/us/podcast/con… 🎧 Spotify: open.spotify.com/episode/75wtyS…

I'll be heading out today to showcase Converge Bio at #biotools. Looking forward to connecting with judges, investors, and fellow entrepreneurs. See you there! #BTIRoadTour2025 #StartupPitch #StartupInnovation #Innovation #LifeSciences

I refuse to mix Shakespeare with amino acids. “Chatty” bio‑LLMs waste model weights on English tokens or bolt giant chat heads onto protein models. Use lean tools like ESM‑2 for folds and ProtGPT‑2 for design, then add a tiny LLM to use the output. Stop paying for bloated prose.

The worst thing about cloud compute is that you don't hear the fans go burrrr